Eli Lilly invests in Oura to aid patients using GLP-1 medicines
read at Endpoints ↗DealPositive
Eli Lilly announced an equity investment in Oura, a startup that makes a wearable health‑monitoring ring.
The partnership is intended to support patients who are prescribed Lilly's GLP-1 medicines by offering digital tools that can track health metrics and medication adherence.
Oura did not disclose the size of the investment, and the deal reflects a growing trend of pharmaceutical companies working with technology firms to improve chronic disease management.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Eli Lilly invests in Oura to support patients on GLP-1 drugs”
read at Endpoints ↗84 words · retrieved Jul 15
comments(0)
5-min edit window · permanent after that